Cornerstone Pharmaceutical-B (02616) was increased by 2,425 million shares by Executive Director Yang Jianxin and executives

Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616) issued an announcement. The company was informed by CEO, President of R&D and Executive Director Yang Jianxin (Dr. Yang), other directors and senior management that they had purchased a total of 2,425 million shares on the open market in June 2026 (this time share increase), of which Dr. Yang purchased 1,237,500 shares.

Since becoming CEO in August 2022, Dr. Yang has purchased a total of 13.714,500 shares on the open market. After the increase in such shares, Dr. Yang held a total of shares equivalent to about 5.26% of the total issued share capital of the Company as of the date of this announcement.

Dr. Yang, other directors and senior management said they are confident in the company's own R&D results, commercialization progress and long-term business development. Specifically, the global multi-center phase II clinical trial of the company's core pipeline CS2009 (PD-1/VEGF/CTLA-4 three-specific antibody) is progressing smoothly. The latest clinical data plans were announced in the mid-term results announcement and the 2026 European Society of Medical Oncology (ESMO) annual meeting, respectively, and plans to communicate with the US Food and Drug Administration (FDA) the Phase III Global Multi-Center Registration Study (MRCT) program by the end of this year to launch the first batch of global phase III MRCTs.

The Company also repurchased a total of 4.597 million shares in June 2026 (this share repurchase), and all repurchased shares are to be cancelled. This share repurchase fully demonstrates the firm confidence of the company in its long-term business development. It also reflects the company's philosophy of attaching great importance to shareholder value returns and continuously improving the capital return mechanism.